BlueCross BlueShield Federal Employee Program

WINREVAIR
PRIOR APPROVAL REQUEST

Additional information is required to process your claim for prescription drugs. Please complete the patient portion, and have the prescribing physician complete the physician portion and submit this completed form.

Send completed form to:
Service Benefit Plan
Prior Approval
P.O. Box 52080 MC 139
Phoenix, AZ 85072-2080
Attn. Clinical Services
Fax: 1-877-378-4727

Patient Information (required)			Provider Information (required)		
Date:			Provider Name:		
Patient Name:			Specialty:	NPI:	
Date of Birth:	Sex: ❑Male ❑Female		Office Phone:	Office Fax:	
Street Address:			Office Street Address:		
City:	State:	Zip:	City:	State:	Zip:
Patient ID: R			Physician Signature:		
PHYSICIAN COMPLETES					

Winrevair
(sotatercept-csrk)

****Check www.fepblue.org/formulary to confirm which medication is part of the patient's benefit**

NOTE: Form must be completed in its **entirety** for processing

Is this request for brand or generic? ❑Brand ❑Generic

1. What is the patient's diagnosis?
   - ❑Pulmonary Arterial Hypertension (PAH) (WHO Group 1)
   - ❑Pulmonary hypertension
     a. What is the cause of the pulmonary hypertension? ***Please select answer below:***
     - ❑Congenital heart disease (WHO Group 1)
     - ❑Connective tissue disease (WHO Group 1)
     - ❑Drugs or toxins induced (WHO Group 1)
     - ❑Heritable PAH (WHO Group 1)
     - ❑HIV infection (WHO Group 1)
     - ❑Idiopathic/**Unknown** cause (WHO Group 1)
     - ❑Portal hypertension (WHO Group 1)
     - ❑Schistosomiasis (WHO Group 1)
     - ❑Other cause ***(please specify)***: _____
     - ❑Persistent pulmonary hypertension of the newborn (PPHN) (WHO Group 1)
     - ❑Pulmonary capillary hemangiomatosis (PCH) (WHO Group 1)
     - ❑Pulmonary veno-occlusive disease (PVOD) (WHO Group 1)
     - ❑Left heart disease (WHO Group 2)
     - ❑Lung disease or hypoxemia (WHO Group 3)
     - ❑Chronic thrombotic or embolic disease (CTEPH) (WHO Group 4)
     - ❑Unclear multifactorial mechanisms (WHO Group 5)
   - ❑Other diagnosis ***(please specify)***: _____
2. **FEMALE Patient**: Is the patient of reproductive potential? ❑Yes* ❑No
   ****If YES***, will the patient be advised to use effective contraception during treatment with Winrevair and for 4 months after the last dose? ❑Yes ❑No
3. Will this medication be used as add-on therapy? ❑Yes ❑No
4. Has the patient been on this medication continuously for the last **6 months**, excluding samples? ***Please select answer below:***

   ❑**NO** – this is **INITIATION** of therapy, please answer the following questions:
   a. Which level of activity causes the patient to experience shortness of breath or fatigue? ***Select answer below:***
   - ❑No symptoms and no limitations in ordinary physical activity (Class I)
   - ❑Mild symptoms and slight limitation during ordinary activity (Class II)
   - ❑Marked limitation in activity due to symptoms, even during less than ordinary activity (Class III)
   - ❑Experiences shortness of breath and fatigue while at rest (Class IV)

   b. Is the patient currently receiving PAH therapy with medications from at least **TWO** of the following drug classes: endothelin receptor antagonists (e.g., Letairis, Opsumit, Tracleer), phosphodiesterase-5 inhibitors (e.g., Adcirca, Revatio), soluble guanylate cyclase stimulators (e.g., Adempas), prostacyclin analogs (e.g., Flolan, Orenitram, Remodulin, Tyvaso, Veletri, Ventavis), or prostacyclin receptor agonists (e.g., Uptravi)? ❑Yes ❑No

   c. Has this medication been prescribed or recommended by either a cardiologist or pulmonologist? ❑Yes ❑No

   ❑**YES** – this is a PA renewal for **CONTINUATION** of therapy, please answer the following question:
   a. Have the patient's symptoms improved or stabilized with therapy? ❑Yes ❑No

